FDA greenlights first vaccine for RSV prevention in infants via active gestational immunization
The Food and Drug Administration its approval of Pfizer’s Abrysvo (Respiratory Syncytial Virus Vaccine), the first vaccine approved for use in pregnant individuals to prevent lower respiratory tract disease and severe LRTD caused by respiratory syncytial virus in infants from birth through six months of age. FDA says Abrysvo is approved for use at 32 through 36 weeks gestational age of pregnancy. The approval follows a clinical study that confirmed Abrysvo’s effectiveness to prevent LRTD and severe LRTD caused by RSV in infants born to individuals who were vaccinated during pregnancy.
Related News Articles
Headline
The American College of Obstetricians and Gynecologists April 17 released guidance recommending a new approach to prenatal care delivery. The guidance calls…
Headline
The National Institutes of Health April 7 released a study that found twins — smaller at birth on average than singletons — develop slower in early pregnancy…
Headline
A National Institutes of Health study published April 2 found that blood pressure patterns observed during the first half of pregnancy can determine a woman's…
Headline
The U.S. birth rate fell 2% in 2023 to about 3.6 million, according to final data released March 18 by the Centers for Disease Control and Prevention. The…
Headline
The Central Nevada Health District yesterday announced the state's first case of H5N1 bird flu, a dairy farm worker who was exposed to infected cattle. The…
Headline
At least 24 million people have had seasonal flu this season, according to estimates from the Centers for Disease Control and Prevention. Nearly 49,000…